We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+38.63%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$566M
AUM Growth
-$36.9M
Cap. Flow
-$112M
Cap. Flow %
-19.7%
Top 10 Hldgs %
52.22%
Holding
76
New
5
Increased
6
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$20.6M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.7M
3
ZLAB icon
Zai Lab
ZLAB
+$9.29M
4
OMER icon
Omeros
OMER
+$8.48M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$7.71M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$23.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$22.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.7M
4
BLUE
bluebird bio
BLUE
+$14.8M
5
NVRO
NEVRO CORP.
NVRO
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRBW
51
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$8K ﹤0.01%
52,999
– –
ABBV icon
52
CALL
AbbVie
ABBV
$455B
– –
-6,100
Closed -$939K
AGEN
53
Agenus
AGEN
$329M
– –
-61,140
Closed -$4.69M
ALNY icon
54
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-125,000
Closed -$9.97M
CHRS icon
55
Coherus Oncology
CHRS
$227M
– –
-620,300
Closed -$8.9M
CLRB icon
56
Cellectar Biosciences
CLRB
$20.2M
– –
-18
Closed -$87K
DXCM icon
57
DexCom
DXCM
$28.8B
– –
-280,000
Closed -$5.12M
FLGT icon
58
Fulgent Genetics
FLGT
$574M
– –
-750,000
Closed -$4.79M
LKFT
59
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
– –
-300,000
Closed -$22.9M
LPCN icon
60
Lipocine
LPCN
$17.4M
– –
-43,617
Closed -$2.98M
RGNX icon
61
Regenxbio
RGNX
$648M
– –
-120,000
Closed -$2.37M
RIGL icon
62
Rigel Pharmaceuticals
RIGL
$704M
– –
-153,975
Closed -$4.2M
XNCR icon
63
Xencor
XNCR
$1.59B
– –
-75,000
Closed -$1.58M
ZYME icon
64
Zymeworks
ZYME
$1.67B
– –
-232,008
Closed -$1.94M
SCTL
65
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-371,518
Closed -$2.34M
MTEM
66
DELISTED
Molecular Templates, Inc.
MTEM
– –
-5,455
Closed -$354K
APTO
67
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-2,201
Closed -$1.22M
MYOV
68
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-100,000
Closed -$1.17M
SRNE
69
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-1,690,800
Closed -$3.38M
HTGM
70
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
– –
-1,130
Closed -$541K
NEOS
71
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-50,613
Closed -$369K
PFNX
72
DELISTED
Pfenex Inc.
PFNX
– –
-574,966
Closed -$2.31M
PTLA
73
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-1,000
Closed -$1.16M
DERM
74
DELISTED
Dermira, Inc.
DERM
– –
-170,000
Closed -$4.95M
SGYP
75
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-1,200,000
Closed -$5.34M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Cormorant Asset Management held 76 positions worth $566M, down 6.1% from $603M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Cormorant Asset Management withdrew a net $112M in Q3 2017, closing 25 positions and reducing 14 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 84% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $12.1M.

  • Cormorant Asset Management's largest Q3 2017 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 388,574 shares worth $12.1M.
  • Cormorant Asset Management added most to Ignyta, Inc. in Q3 2017, an estimated $20.6M increase.
  • Cormorant Asset Management's biggest Q3 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $23.5M.
  • Cormorant Asset Management fully exited Lakefront Biotherapeutics American Depositary Shares in Q3 2017, selling an estimated $22.9M.
  • Cormorant Asset Management's ten largest holdings make up 52% of its $566M portfolio in Q3 2017.
  • Cormorant Asset Management opened 5 new positions and closed 25 in Q3 2017.
  • Cormorant Asset Management's portfolio value fell 6.1% quarter-over-quarter to $566M.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.